Subscribe to RSS
DOI: 10.1055/s-2002-20501
Atypische Neuroleptika in der Behandlung von Aggressivität und Feindseligkeit bei schizophrenen Patienten
Atypical Neuroleptics in the Treatment of Aggression and Hostility in Schizophrenic PatientsPublication History
Publication Date:
04 March 2002 (online)
![](https://www.thieme-connect.de/media/fdn/200203/lookinside/thumbnails/10.1055-s-2002-20501-1.jpg)
Zusammenfassung
Die Behandlung aggressiver Symptome bei schizophrenen Patienten ist sowohl ein klinisches als auch gesellschaftlich relevantes Problem. Der vorliegende systematische Literaturüberblick stellt nach einer Darstellung allgemeiner methodischer Probleme die bisher existierenden Untersuchungen zu der Wirksamkeit atypischer Neuroleptika vor dem Hintergrund von Akut- und Langzeittherapie und der Verfügbarkeit verschiedener Applikationsformen der Medikamente dar. In der Akuttherapie aggressiver Symptome werden die klassischen Neuroleptika immer noch als Mittel der ersten Wahl angesehen, obwohl Risperidon und Olanzapin mögliche Alternativen darstellen. Insbesondere bei persistierender oder wiederkehrender aggressiver Symptomatik scheint aber für Clozapin bisher die beste, spezifisch antiaggressive Wirksamkeit bei geringeren Nebenwirkungen nachgewiesen. Bei medikamentöser Noncompliance muss auf klassische Depotpräperate zurückgegriffen werden.
Abstract
The treatment of aggressive symptoms in schizophrenic patients is a relevant clinical problem. We systematically review the efficacy of the different atypical neuroleptics on acute or persistent aggressive symptoms also regarding methodological problems. Currently typical neuroleptics are still first choice in treating acute aggressive symptoms, while risperidone and olanzapine could be alternatives. In persistent aggression clozapin shows the best specific results. Typical depot neuroleptics should be considered in cases when medication compliance is a problem.
Literatur
- 1 Swanson J, Holzer C, Gantu V. Violence and psychiatric epidemiologic catchment area surveys. Hosp Comm Psych. 1990; 41 761-770
- 2 Citrome L, Volavka J. Schizophrenia: violence and comorbidity. Current Opinion in Psychiatry. 1999; 12 47-51
- 3 Wessely S. The epidemiology of crime, violence and schizophrenia. Br J Psych. 1997; 170 (Suppl.) 32 8-11
- 4 Hunter M, Carmel I. The cost of staff injuries from inpatient violence. Hosp Comm Psych. 1992; 43 586-588
- 5 Pajonk F G, Grunberg K A, Paschen H R, Moecke H. Psychiatrische Notfälle im Notarztdienst einer deutschen Großstadt. Fortschr Neurol Psychiatr. 2001; 69 170-174
- 6 Weiden P J, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995; 21 419-429
- 7 Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psych. 1999; 60 (Suppl. 12) 43-46
- 8 McNeil D. Correlates of violence in psychotic patients. Psychiatr Ann. 1997; 27 683-690
- 9 Buckley P F. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psych. 1999; 60 (Suppl. 10) 52-60
- 10 Kalin N H. Primate models to understand human aggression. J Clin Psych. 1999; 60 (Suppl. 15) 29-32
- 11 Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive aggression. Psych Clin North Amer. 1997; 20 395-403
- 12 Schmahl C, Bohus M. Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörungen. Fortschr Neurol Psychiatr. 2001; 69 310-321
- 13 Brieden T, Naber D. Psychopharmacological treatment of aggression in schizophrenic and other psychiatric patients (submitted).
- 14 Briken P, Berner W, Noldus J, Nika E, Michl U. Therapie mit dem LHRH-Agonisten Leuprorelinacetat bei Paraphilien und sexuell aggressiven Impulshandlungen. Nervenarzt. 2000; 71 380-385
- 15 Volavka J, Citrome L. Atypical antipsychotics in the treatment of the presistently aggressive psychotic patient: methodologic concerns. Schizophr Res. 1999; 35 (Suppl.) 23-33
- 16 Kay S R, Wolkenfeld F, Murrill L M. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis. 1988; 176 539-546
- 17 Rasmussen K, Levander S. Symptoms and personality characteristics of patients in a maximum security psychiatric unit. Int J Law Psychiatry. 1996; 19 27-37
- 18 Wilson W H. Clinical review of clozapine treatment in a state hospital. Hosp Comm Psych. 1992; 34 700-703
- 19 Ebrahim G M, Gibler B, Gacono G B. Patients response to clozapine in a forensic psychiatric hospital. Hosp Comm Psych. 1994; 45 271-273
- 20 Chiles J A, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Comm Psych. 1994; 45 269-271
- 21 Mallya A R, Roos P D, Roebuck-Colgan K. Restraint, seclusion and clozapine. J Clin Psychiatry. 1992; 53 395-397
- 22 Maier G J. The impact of clozapine on 25 forensic patients. Bull Am Acad Psychiatry Law. 1992; 20 297-307
- 23 Volavka J, Zito J M, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol. 1993; 13 287-289
- 24 Ratey J J, Leveroni C, Kilmer D, Gutheil C, Swartz B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psych. 1993; 54 219-223
- 25 Buckley P F, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz S C. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psych Law. 1995; 23 607-611
- 26 Wilson W H, Claussen A M. 18-month outcome of clozapine treatment for 100 patients in a state hospital. Psychiatr Serv. 1995; 46 386-389
- 27 Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996; 22 249-255
- 28 Pinals D A, Buckley P F. Novel antipsychotic agents and their implications for forensic psychiatry. J Am Acad Psych Law. 1999; 27 7-22
- 29 Naber D, Lambert M, Krausz M, Haasen Ch. Atypische Neuroleptika in der Behandlung der Schizophrenie. Bremen: UNI-Med 2001
- 30 Czobor P, Volavka J, Meibach R. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995; 15 243-249
- 31 Chengappa K NR, Levine J, Ulrich R, Parepelly H, Brar J S, Atzert R, Brienzo R, Gopelani A. Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can J Psychiatry. 2000; 45 827-832
- 32 Buckley P F, Ibrahim Z Y, Singer B, Orr B, Donenwirth K, Brar P S. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law. 1997; 25 173-181
- 33 Beck N C, Greenfield S R, Gotham H, Menditto A A, Stuve P, Hemme C A. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law. 1997; 25 461-468
- 34 Beasley C M, Saylor M E, Kiesler G M. et al . The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia [abstract]. Schizophr Res. 1998; 29 28
- 35 Wright P, Birkett M, Davis S R, Meehan K, Ferchland I, Alaka K J, Saunders J C, Krueger J, Bradley P, San L, Bernando M, Reinstein M, Beier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psych. 2001; 158 1149-1151
- 36 Cantillon M, Arvanitis L A, Miller B G, Kowalcyk B B. “Seroquel” (quetiapine fumarate) reduces hostility and aggression in patients with acute schizophrenia: Proceedings of the 36th annual meeting of the American College of Neuropsychopharmacology. Honolulu, Hawaii (Abstract) 1997: 171
- 37 Brook S, Krams M, Gunn K P. The efficacy and tolerability of intramuscular (i. m.) ziprasidone versus i. m. haloperidol in patients with acute, non-organic psychosis. Presented at the 1010 annual meeting of the European College of Neuropsychopharmacology. Austria 1997
- 38 Reeves K R, Swift R H, Harrigan E P. A comparison of rapid acting, intramuscular (i. m.) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. Presented at the annual meeting of the Collegium Internationale Neuropsychopharmacologium. Glasgow, Scotland 1998
- 39 Lee A M, Knoll J L, Suppes T. The atypical antipsychotic sertindole: a case series [CME]. J Clin Psychiatry. 1997; 58 410-416
- 40 Briken P, Nika E, Moritz S, Haasen Ch, Perro C, Yagdiran O, Naber D, Krausz M. Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophr Res (in press).
- 41 Wetterling T. Gewichtszunahme bei Gabe von atypischen Neuroleptika - eine unterschätzte Nebenwirkung?. Fortschr Neurol Psychiatr. 2000; 68 546-556
- 42 Swartz M S, Swanson J W, Hiday V A, Borum R, Wagner H R, Burns B J. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry. 1998; 155 226-231
Dr. med. P. Briken
Abteilung für Sexualforschung und Forensische Psychiatrie
Zentrum für psychosoziale Medizin, Psychiatrie und Psychotherapie des Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Email: briken@uke.uni-hamburg.de